Crossmark

Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions

Crossref DOI link: https://doi.org/10.1136/jitc-2022-005016

Published Online: 2022-10-19

Published Print: 2022-10

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Speetjens, Frank M https://orcid.org/0000-0003-2065-9593
Welters, Marij J P

Slingerland, Marije

van Poelgeest, Mariette I E

de Vos van Steenwijk, Peggy J

Roozen, Inge

Boekestijn, Sanne

Loof, Nikki M

Zom, Gijs G

Valentijn, A Rob P M

Krebber, Willem-Jan

Meeuwenoord, Nico J

Janssen, Catharina A H

Melief, Cornelis J M

van der Marel, Gijs A

Filippov, Dmitri V

van der Burg, Sjoerd H

Gelderblom, Hans

Ossendorp, Ferry
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct02821494 at ClinicalTrials.gov

Documents that mention this clinical trial

Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions
https://doi.org/10.1136/jitc-2022-005016
License Information

License valid from 2022-10-19

Document is current

Any future updates will be listed below